Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype
Publication year
2022Source
Oncoimmunology, 11, 1, (2022), article 2094133ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Medical Oncology
Tumorimmunology
Pathology
Urology
Journal title
Oncoimmunology
Volume
vol. 11
Issue
iss. 1
Subject
Radboudumc 15: Urological cancers RIHS: Radboud Institute for Health Sciences; Radboudumc 15: Urological cancers RIMLS: Radboud Institute for Molecular Life Sciences; Radboudumc 2: Cancer development and immune defence RIHS: Radboud Institute for Health Sciences; Radboudumc 2: Cancer development and immune defence RIMLS: Radboud Institute for Molecular Life Sciences; Radboudumc 9: Rare cancers RIMLS: Radboud Institute for Molecular Life Sciences; Medical Oncology - Radboud University Medical Center; Pathology - Radboud University Medical Center; Radboud University Medical Center; Tumorimmunology - Radboud University Medical Center; Urology - Radboud University Medical CenterThis item appears in the following Collection(s)
- Academic publications [243399]
- Electronic publications [129913]
- Faculty of Medical Sciences [92493]
- Open Access publications [104442]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.